ACRP Announces Task Force to Develop Clinical Research Associate Competencies
Washington, DC – The Association of Clinical Research Professionals (ACRP) today announces formation of a multi-stakeholder task force charged with defining the core competencies required of entry-level clinical research associates (CRAs).
The task force will identify the competencies required of entry-level CRAs (also known as monitors), develop measures of competence, and advocate for standardization of identified CRA competencies across the clinical research enterprise.
This announcement follows publication this week by ACRP of a position paper examining the current CRA workforce and calling for elimination of the commonly accepted and practiced two-year experience requirement for entry-level CRAs in favor of competence-based employment practices (see: A New Approach to Developing the CRA Workforce).
"The arbitrary 2-years' experience requirement is contributing to a shortage of CRAs in the clinical research profession and is leading to inefficiencies at contract research organization and clinical trial sponsors while doing nothing to ensure quality in clinical research," says Terri Hinkley, RN, BScN, MBA, CCRC, ACRP Interim Executive Director. "By leading this initiative ACRP plans to drive a shift in the profession that will both address the existing workforce pipeline issues and improve the quality conduct of clinical research."
As noted in ACRP's position paper, there are at least 10,000 CRA open positions in the United States alone, and there is no evidence to suggest that number will decline any time soon. A recent Brookings study, lamenting an overall employee shortage throughout the life sciences industry, singled out the CRA as one of the positions most in need of recruitment.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
